ESC Professional Premium Access

Clinician perceptions and reasons for non-use of guideline-directed medical therapy for heart failure with reduced ejection fraction in the United States

Congress Presentation

About the speaker

Doctor Stephen Greene

Duke Clinical Research Institute, Durham (United States of America)
9 presentations
1 follower

7 more presentations in this session

Left ventricular reverse remodeling following initiation of sacubitril/valsartan for heart failure with reduced ejection fraction and low blood pressure

Speaker: Doctor Y. Nishihara (Kobe, JP)

Thumbnail

Real world data on adopting guideline directed medical therapy post 2021 ESC HF guidelines and effect on renal function.

Speaker: Mr M. Ferrari (Brescia, IT)

Thumbnail

Use of guideline-recommended heart failure drugs in high-, middle- and low-income countries: a systematic review and meta-analysis

Speaker: Associate Professor S. Peters (Utrecht, NL)

Thumbnail

Candidacy and predicted efficacy of vericiguat in contemporary heart failure outpatient clinics

Speaker: Doctor B. Soh (Waterford, IE)

Thumbnail

Quadruple therapy for heart failure before and after electronic cardiac device implantation - are we hitting our targets?

Speaker: Doctor F. Rode (Zagreb, HR)

Thumbnail

Access the full session

Pharmacotherapy in heart failure

Speakers: Doctor S. Greene, Doctor Y. Nishihara, Mr M. Ferrari, Associate Professor S. Peters, Doctor B. Soh...
Thumbnail

About the event

Image

ESC Congress 2023

25 August - 28 August 2023

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb